Literature DB >> 7968248

Excitatory amino acids: implications for psychiatric disorders research.

M Toru1, A Kurumaji, M Ishimaru.   

Abstract

The hyperdopaminergic theory of schizophrenia may account for some types of schizophrenia, but schizophrenia with negative symptoms or resulting in a chronic state of deterioration after repeated relapses cannot be explained by this theory. This minireview first discusses the interactions between dopamine and excitatory amino acid (EAA) neurons to produce abnormal behavior. Secondly, it deals with the influence of the psychotropic drugs on EAA, such as the relationship between phencyclidine and the hypoglutamate theory, the involvement of EAA in behavioral sensitization induced by amphetamines, the interactions between antipsychotic, antidepressant and antianxiety drugs and EAA, considering the possibility of developing newer psychotropic drugs related with EAA. Finally, glutamate receptors measured in postmortem schizophrenic brains are tabulated and the bases of the hypoglutamate hypothesis are discussed.

Entities:  

Mesh:

Substances:

Year:  1994        PMID: 7968248     DOI: 10.1016/0024-3205(94)00337-8

Source DB:  PubMed          Journal:  Life Sci        ISSN: 0024-3205            Impact factor:   5.037


  4 in total

1.  Chronic lithium treatment robustly protects neurons in the central nervous system against excitotoxicity by inhibiting N-methyl-D-aspartate receptor-mediated calcium influx.

Authors:  S Nonaka; C J Hough; D M Chuang
Journal:  Proc Natl Acad Sci U S A       Date:  1998-03-03       Impact factor: 11.205

2.  Blockade of phencyclidine-induced effects by a nitric oxide donor.

Authors:  M Bujas-Bobanovic; D C Bird; H A Robertson; S M Dursun
Journal:  Br J Pharmacol       Date:  2000-07       Impact factor: 8.739

3.  Conventional and atypical antipsychotics in the elderly : a review.

Authors:  Pietro Gareri; Pasquale De Fazio; Mariagrazia Stilo; Guido Ferreri; Giovambattista De Sarro
Journal:  Clin Drug Investig       Date:  2003       Impact factor: 2.859

4.  Antipsychotic treatments; focus on lurasidone.

Authors:  Tomiki Sumiyoshi
Journal:  Front Pharmacol       Date:  2013-08-26       Impact factor: 5.810

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.